Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

This study has been completed.

Sponsored by:	Saitama Medical University
Information provided by:	Saitama Medical University
ClinicalTrials.gov Identifier:	NCT00530595

Purpose

Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Condition	Intervention
Cardiovascular Disease	Drug: candesartan or valsartan or losartan

MedlinePlus related topics: Dialysis Kidney Failure

Drug Information available for: Valsartan Candesartan cilexetil CV 11974 Losartan Losartan potassium

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment

Eligibility

Ages Eligible for Study:	30 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

30 to 80 years of age
Receiving hemodialysis at least 12 months and less than 5 years
Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

Exclusion Criteria:

Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00530595

Sponsors and Collaborators

Saitama Medical University

Investigators

Study Director:

Hiromichi Suzuki, MD, PhD

Department of Nephrology, Saitama Medical University

More Information

Publications indexed to this study:

Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):501-6. Epub 2008 Jul 24.

Study ID Numbers:	S-01
Study First Received:	September 13, 2007
Last Updated:	September 14, 2007
ClinicalTrials.gov Identifier:	NCT00530595
Health Authority:	Japan: Institutional Review Board

Keywords provided by Saitama Medical University:

hemodialysis

Study placed in the following topic categories:

Candesartan cilexetil
Losartan
Candesartan
Angiotensin II
Valsartan

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Cardiovascular Diseases

Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009